Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 may protect against cognitive impairment in rats of chronic cerebral hypoperfusion via PI3K/AKT signaling

2016 ◽  
Vol 313 ◽  
pp. 334-344 ◽  
Author(s):  
Shao-Hua Su ◽  
Yue-Qing Wang ◽  
Yi-Fang Wu ◽  
Da-Peng Wang ◽  
Qi Lin ◽  
...  
Addiction ◽  
2008 ◽  
Vol 103 (10) ◽  
pp. 1678-1686 ◽  
Author(s):  
Heather M. Haughey ◽  
Erin Marshall ◽  
Joseph P. Schacht ◽  
Ashleigh Louis ◽  
Kent E. Hutchison

2016 ◽  
Vol 74 ◽  
pp. 21-27 ◽  
Author(s):  
Andrea Pirone ◽  
Carlo Cantile ◽  
Vincenzo Miragliotta ◽  
Carla Lenzi ◽  
Elisabetta Giannessi ◽  
...  

2021 ◽  
Author(s):  
Alex Mabou Tagne

The endocannabinoid system (ECS) modulates a variety of physiological processes, attracting considerable attention as a potential target for therapeutic intervention. This complex system is activated by the lipid-derived mediators anandamide and 2-arachidonoyl-sn-glycerol (2-AG), which mainly engage the cannabinoid receptor subtypes 1 (CB1) and 2 (CB2). The biological actions of anandamide and 2-AG are terminated by internalization and intracellular enzymatic hydrolysis catalyzed primarily by the serine hydrolases fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL), respectively. Here, we provide an overview of ECS and discuss the implications for advancing pharmacological tools that interfere with such a system as next-generation therapeutics. This review contains 4 figures, 3 tables and 41 references Keywords: Endocannabinoid; anandamide; 2-Arachidonoyl-sn-glycerol; fatty acid amide hydrolase; monoacylglycerol lipase; cannabinoid receptors; N-acylethanolamine acid amidase; Δ9-tetrahydrocannabinol.


2013 ◽  
Vol 74 (6) ◽  
pp. 867-878 ◽  
Author(s):  
L. Cinnamon Bidwell ◽  
Jane Metrik ◽  
John McGeary ◽  
Rohan H. C. Palmer ◽  
S. Francazio ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document